The following publication discusses the latest research regarding the Non-Invasive Biomarkers of Nonalcoholic Steatohepatitis (NASH). Nature Medicine originally published this article, coauthored by ERG’s Vice President of Clinical Pharmacology Services Clay Dehn, on February 10th, 2022.
We are conducting a research study to better understand and develop effective treatments for opioid use disorder. Your participation can make a significant difference in the fight against opioid addiction. If you are struggling with opioid use disorder, you may qualify for a paid clinical trial. Your privacy is a priority and all Information collected will be kept confidential. Learn more today.
